Toppublicaties

Melanoom

Geselecteerd door: Melanoom
  • september 2022

Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: The DREAMseq Trial - ECOG-ACRIN EA6134

  • Michael B Atkins, Sandra J Lee, Bartosz Chmielowski, et al.
  • september 2022

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

  • Jeffrey S Weber, Dirk Schadendorf, Michele Del Vecchio, et al.
  • september 2022

LBA6 - Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801)

  • S. Patel, M. Othus, V. Prieto, et al.
Duiding door Dr. Sofie Wilgenhof

Tumor-infiltrerende lymfocyten effectief bij vergevorderd melanoom
  • september 2022

LBA3 - Treatment with tumor-infiltrating lymphocytes (TIL) versus ipilimumab for advanced melanoma: Results from a multicenter, randomized phase III trial

  • J.B.A.G. Haanen, M. Rohaan, T.H. Borch, et al.
  • september 2022

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial

  • Paolo A Ascierto, Mario Mandalà, Pier Francesso Ferrucci, et al.
  • augustus 2022

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma

  • Jason A Chesney, Antoni Ribas, Georgina V Long, et al.
  • juni 2022

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.

  • Reijers I.L.M., Menzies A. M., van Akkooi A. C. J.
  • mei 2022

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma.

  • Dummer R., Long G.V, Robert C., et al.
  • april 2022

Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).

  • Postow M.A.. Goldman D.A., Shoushtari A.N., et al
Duiding door Dr. Sofie Wilgenhof

Combinatie relatlimab-nivolumab zorgt niet voor betere overleving bij uitgezaaid melanoom
  • maart 2022

Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047)

  • Georgina V. Long, F. Stephen Hodi, Evan J. Lipson, et al.
  • januari 2022

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma

  • Dummer R, Long GV, Robert C, et al.
Duiding door Dr. S. Wilgenhof

Combinatie relatlimab-nivolumab zorgt niet voor betere overleving bij uitgezaaid melanoom
  • januari 2022

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

  • Tawbi HA, Schadendorf D, Lipon EJ, et al.
Gedownload van https://medischeoncologie.nl/ op 22-03-2023 om 12:59. Copyright (C) 2023 BPM Medica.

Deel deze pagina